Exchange: NASDAQ·Updated 07:56 PM EDT
News
all
press releases
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS PR Newswire SINGAPORE, Aug. 2, 2026 Minjuvi (tafasitamab), in combination with rituximab and lenalidomide, is the first...
PR Newswire
More News
Here's Why Incyte (INCY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod
The European Commission on Wednesday approved Incyte’s Opzelura cream as the first steroid-free topical treatment of its kind for adults with moderate eczema who do not get enough relief from standard creams.
Stocktwits
Here's Why Incyte (INCY) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Opzelura (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Opzelura (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate...
Business Wire
Incyte Says It's No Longer A One-Drug Story
Incyte (INCY) Q2 earnings beat estimates with $1.67B revenue, $3.09 EPS. Full-year sales guidance raised. Shares rally to new 52-week high.read more...
Benzinga
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
Zacks
Incyte Q2 Revenue Jumps 38%, Raises FY26 Sales Guidance
(RTTNews) - Incyte Corp. (INCY) on Tuesday reported an increase in second-quarter earnings and revenue, driven by strong growth across its commercial portfolio. The company also raised its full-year 2026 sales guidance...
Nasdaq News: Markets
James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition
James Michael Morrissey, EVP at Incyte (NASDAQ:INCY), reported acquisition of company stock options on July 27, according to a new SEC filing. What Happened: Uncovered in a Form 4 filing on Monday with the U.S.read more...
Benzinga
A Noteworthy Decision By Lee Heeson As Acquires $130K In Incyte Stock Options
In a new SEC filing on July 27, it was unveiled that Heeson, EVP at Incyte (NASDAQ:INCY), acquired stock options for 15,423 shares. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission onread more...
Benzinga
<
1
2
>

Advertisement|Remove ads.